Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Incyte Corporation : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings in line with the consensus. In recent months, the 15 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at 0.41 USD for 2018 (- 126.8% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread

736
1 106
1 106
0,01%
1 536
1 518
1,2%



2 018
Operating income (EBITDA)
Million $
Released
Forecast
Spread
95,5
48,6
97%
203
199
2,1%
-192
-171
-12%

294

484
Operating profit (EBIT)
Million $
Released
Forecast
Spread
50,7
14,4
251%
145
118
23%
-244
-218
-12%

211

437
Pre-Tax Profit (EBT)
 
Released
Forecast
Spread










Net income
Million $
Released
Forecast
Spread

-34,7
101
120
-16%
-313
-236
-33%

100

292
EPS
 $
Released
Forecast
Spread
0,03
-0,19
116%
0,54
0,62
-13%
-1,53
-1,17
-31%

0,41

1,36
Announcement Date11/30/-000102/14/201702/15/2018

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INCYTE CORPORATION
04/11INCYTE : to Report First Quarter Financial Results
BU
04/03BRIACELL THERAPEUTICS : Announces Clinical Trial Collaboration Agreement with In..
AQ
04/02INCYTE : BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
AQ
04/01INCYTE : Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR ..
AQ
03/01INCYTE : Data from Incyte's Cancer Research Portfolio to be featured in Seven Ab..
AQ
02/28INCYTE : Summary ToggleIncyte Joins Patient Organizations Worldwide in Recognizi..
PU
02/28INCYTE : Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2..
BU
02/28INCYTE : Summary ToggleData from Incyte's Cancer Research Portfolio to be Featur..
PU
02/28INCYTE : Data from Incyte's Cancer Research Portfolio to be Featured in Seven Ab..
BU
02/19INCYTE : Summary ToggleIncyte to Present at Upcoming Investor Conferences
PU
More news
Financials ($)
Sales 2019 2 059 M
EBIT 2019 394 M
Net income 2019 298 M
Finance 2019 1 549 M
Yield 2019 -
P/E ratio 2019 59,27
P/E ratio 2020 35,80
EV / Sales 2019 6,98x
EV / Sales 2020 5,76x
Capitalization 15 924 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 89,3 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Dashyant Dhanak Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION21.06%15 924
IQVIA HOLDINGS INC13.89%26 146
CELLTRION, INC.--.--%23 477
LONZA GROUP14.29%21 459
EXACT SCIENCES CORPORATION45.50%11 546
SEATTLE GENETICS, INC.35.37%11 396